• If you are wondering whether Collegium Pharmaceutical's current share price reflects its underlying worth, starting with a clear look at value can help frame your next move.
• The stock last closed at US$34.32, with returns of 5.6% over the past week, 6.2% over the past month, a 24.6% decline year to date, and 24.1% over the past year. Taken together, this gives you a mixed picture of recent performance.
• Recent coverage around Collegium has focused on its position in the pharmaceuticals space and how investors weigh its long term prospects against sector wide risks and competition. This context helps explain why the share price has seen both periods of strength and setbacks across different time frames.
• Collegium currently has a valuation score of 5 out of 6. The next sections will walk through what traditional valuation methods say about the stock and will also point you to a broader way of thinking about value at the end of the article.

Approach 1: Collegium Pharmaceutical Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a business could be worth by projecting the cash it may generate in the future and then discounting those cash flows back to today using a required rate of return.

For Collegium Pharmaceutical, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $327.8 million. Analyst inputs and extrapolations from Simply Wall St then project free cash flows through to 2035, including an estimate of $277.5 million in 2030, all in US$.

Bringing all of those projected cash flows back to today results in an estimated intrinsic value of about $184.04 per share under this DCF model. Compared with the recent share price of $34.32, the DCF output suggests the stock is 81.4% undervalued according to these assumptions and inputs.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Collegium Pharmaceutical is undervalued by 81.4%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Collegium Pharmaceutical Price vs Earnings

For profitable companies, the P/E ratio is a useful shorthand for how much investors are currently paying for each dollar of earnings, so it is a practical check against the more detailed DCF view you saw earlier.

What counts as a “normal” P/E depends on how the market views a company’s growth potential and risk profile. Higher expected earnings growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk can be associated with a lower one.

Collegium Pharmaceutical currently trades on a P/E of 17.69x. This sits close to the Pharmaceuticals industry average of 17.02x and well below the peer group average of 54.25x. Simply Wall St’s proprietary Fair Ratio for Collegium is 23.74x, which is the P/E level suggested after considering factors such as its earnings growth profile, profit margins, industry, market capitalization and company specific risks.

The Fair Ratio offers a more tailored anchor than a simple comparison with peers or the broad industry, as it adjusts for company specific characteristics rather than treating all pharmaceutical stocks as alike. Since Collegium’s actual P/E of 17.69x is below the Fair Ratio of 23.74x, this approach points to the shares trading at a discount on earnings.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Collegium Pharmaceutical Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story about Collegium Pharmaceutical to the numbers by tying your view on its future revenues, earnings and margins to a forecast, which then links through to a fair value, updates automatically when fresh news or earnings arrive, and helps you decide what to do by comparing that fair value with the current price, whether you lean closer to the most optimistic analyst narrative that sees room for a US$60.00 outcome or the more cautious one that points to US$44.00. All of this is presented within an easy to use Community page that shows how other investors are thinking about the same stock.

Do you think there's more to the story for Collegium Pharmaceutical? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.